by goodDayM
Source: The COVID-19 vaccine development landscape (nature.com)
| Developer | Candidate | Vaccine Characteristics | Status |
|---|---|---|---|
| Moderna | mRNA-1273 | LNP-encapsulated mRNA vaccine encoding S protein | Phase I (NCT04283461) |
| CanSino Biologicals | Ad5-nCoV | Adenovirus type 5 vector that expresses S protein | Phase I (NCT04313127) |
| Inovio Pharmaceuticals | INO-4800 | DNA plasmid encoding S protein delivered by electroporation | Phase I (NCT04336410) |
| Shenzhen Geno-Immune Medical Institute | LV-SMENP-DC | DCs modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific CTLs | Phase I (NCT04276896) |
| Shenzhen Geno-Immune Medical Institute | Pathogen-specific aAPC | aAPCs modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins | Phase I (NCT04299724) |
There are dozens of other vaccine candidates in development:
Of the confirmed active vaccine candidates, 56 (72%) are being developed by private/industry developers, with the remaining 22 (28%) of projects being led by academic, public sector and other non-profit organizations. Although a number of large multinational vaccine developers (such as Janssen, Sanofi, Pfizer and GlaxoSmithKine) have engaged in COVID-19 vaccine development, many of the lead developers are small and/or inexperienced in large-scale vaccine manufacture.
Disclaimer: This information is only for educational purposes. Do not make any investment decisions based on the information in this article. Do you own due diligence.